MAR vs PFE: Which Is the Better Buy?
Side-by-side comparison of Marriott International, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-18.
Marriott International, Inc. · Consumer Cyclical
$377.93
-16.6% upside to fair value
Grade D
VS
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction
Grade B+
QuantHub Verdict
PFE has more upside to fair value
(+30.1%).
PFE trades at a lower forward P/E
(9.5x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MAR |
PFE |
| Current Price |
$377.93 |
$26.91 |
| Fair Value Estimate |
$315.15 |
$35.00 |
| Upside to Fair Value |
-16.6%
|
+30.1%
|
| Market Cap |
$100.2B |
$153.0B |
| Forward P/E |
39.0x
|
9.5x
|
| EV / EBITDA |
25.3x
|
13.8x
|
| Price / Sales |
3.8x
|
2.4x
|
| Price / FCF |
34.6x
|
16.8x
|
| Revenue Growth YoY |
+3.1%
|
-1.6%
|
| Gross Margin |
21.3%
|
70.3%
|
| Operating Margin |
15.8%
|
24.7%
|
| Return on Equity |
-79.9%
|
9.0%
|
| Dividend Yield |
0% |
6.4% |
| FCF Yield |
2.89%
|
5.9%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Marriott International operates the world's largest hospitality portfolio with approximately 8,900 to 9,000 properties across 141 countries and over 30 brands, supported by the largest loyalty program with 203 to 210 million members. The company benefits from a durable competitive moat driven by scale, brand strength, and network effects. However, despite steady revenue growth of 3.1% year-over-y…
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
Accumulation Zones
| Metric |
MAR |
PFE |
| Zone Low |
$236.36 |
$25.00 |
| Zone High |
$267.88 |
$29.00 |
| In Buy Zone? |
No
|
Yes
|